Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive)

Trial Profile

Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Alefacept (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms T1DAL
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2016 Results of a post hoc analysis of glycemic control data published in the Clinical Therapeutics
    • 28 Oct 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top